Verve Therapeutics, Inc. (VERV)

Investigation 

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or the "Company") (NASDAQ: VERV). Investors who purchased Verve Therapeutics, Inc. securities are encouraged to obtain additional information and assist the investigation.         

 

The investigation concerns whether Verve and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

 

On October 31, 2022, Verve issued a press release “announc[ing] that preclinical data supporting VERVE-101 as a treatment for heterozygous familial hypercholesterolemia (HeFH), a genetic form of atherosclerotic cardiovascular disease (ASCVD), has been published in the American Heart Association’s peer-reviewed journalCirculation.”  According to the preclinical data reported by the Company, VERVE-101 did not demonstrate significantly greater efficacy than statins, the traditional treatment for patients with high cholesterol.  On this news, Verve’s stock price fell $3.00 per share, or 7.37%, to close at $37.70 per share on October 31, 2022.  Then, on November 7, 2022, Verve announced that “the U.S. Food and Drug Administration (FDA) has placed a hold on its IND application to conduct a clinical trial evaluating VERVE-101 in patients with heterozygous familial hypercholesterolemia (HeFH) . . . in the United States.”  On this news, Verve’s stock price fell $9.54 per share, or 30.49%, to close at $21.75 per share on November 7, 2022.  Then, on December 5, 2022, Verve disclosed that the FDA had requested additional data to resolve the clinical hold.  On this news, Verve’s stock price fell $2.58 per share, or 10.75%, to close at $21.42 per share on December 5, 2022.

 

If you are aware of any facts relating to this investigation or purchased Verve Therapeutics, Inc. shares, you can assist this investigation. You can also contact Peretz Bronstein or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.  The firm has recovered hundreds of millions of dollars for investors nationwide.  Attorney advertising. Prior results do not guarantee similar outcomes.